评估卡波莫瑞林对猕猴的安全性和有效性

Gianni A Campellone, Kirk A Easley, Joe B Jenkins, Sherrie M Jean
{"title":"评估卡波莫瑞林对猕猴的安全性和有效性","authors":"Gianni A Campellone, Kirk A Easley, Joe B Jenkins, Sherrie M Jean","doi":"10.30802/AALAS-JAALAS-23-000010","DOIUrl":null,"url":null,"abstract":"<p><p>Nonhuman primates used in biomedical research may experience clinically significant weight loss for a variety of reasons. Episodes of anorexia (complete loss of appetite) or hyporexia (decreased appetite) can result in significant weight loss, potentially altering animal welfare and scientific studies. The FDA has approved several appetite stimulants for use in domestic species, but currently none are approved for use in NHP. Treatment of inappetence and weight loss in NHP often relies on the extralabel use of these compounds. Capromorelin is a ghrelin receptor agonist. As a growth hormone secretagogue, capromorelin increases appetite, leading to weight gain. Studies in several species have shown a positive correlation between capromorelin administration and weight gain; in 2017, an oral solution of capromorelin received FDA approval for use in dogs. We tested this solution in healthy adult rhesus macaques (n = 3 males and 3 females) for its effects on body weight and insulin like growth factor-1 (IGF-1). A control group (n = 2 males and 2 females) was used for comparison. Treated macaques received a 3mg/kg oral dose daily for 7 d. Clinical signs were observed daily. Weights were collected before, during and at the end of treatment. Blood was drawn before, during and after treatment for measurement of IGF-1 levels and standard hematology and biochemistry parameters. Baseline-adjusted mean body weights and IGF-1 levels were significantly higher in treated as compared with control monkeys after 7 d of beginning treatment (body weight of 10.5±0.1kg (mean ± SEM) and 10.1±0.1kg, respectively; IGF-1 of 758±43ng/mL and 639±22ng/mL, respectively). Capromorelin administration was not associated with appreciable changes in hematologic and biochemical values in treated macaques. These findings suggest that capromorelin may be useful for treating inappetence and weight loss in NHP, and based on blood analysis, a 7-d course of treatment does not appear to cause acute toxicity.</p>","PeriodicalId":94111,"journal":{"name":"Journal of the American Association for Laboratory Animal Science : JAALAS","volume":" ","pages":"268-278"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11193426/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluating the Safety and Efficacy of Capromorelin in Rhesus Macaques (<i>Macaca mulatta</i>).\",\"authors\":\"Gianni A Campellone, Kirk A Easley, Joe B Jenkins, Sherrie M Jean\",\"doi\":\"10.30802/AALAS-JAALAS-23-000010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Nonhuman primates used in biomedical research may experience clinically significant weight loss for a variety of reasons. Episodes of anorexia (complete loss of appetite) or hyporexia (decreased appetite) can result in significant weight loss, potentially altering animal welfare and scientific studies. The FDA has approved several appetite stimulants for use in domestic species, but currently none are approved for use in NHP. Treatment of inappetence and weight loss in NHP often relies on the extralabel use of these compounds. Capromorelin is a ghrelin receptor agonist. As a growth hormone secretagogue, capromorelin increases appetite, leading to weight gain. Studies in several species have shown a positive correlation between capromorelin administration and weight gain; in 2017, an oral solution of capromorelin received FDA approval for use in dogs. We tested this solution in healthy adult rhesus macaques (n = 3 males and 3 females) for its effects on body weight and insulin like growth factor-1 (IGF-1). A control group (n = 2 males and 2 females) was used for comparison. Treated macaques received a 3mg/kg oral dose daily for 7 d. Clinical signs were observed daily. Weights were collected before, during and at the end of treatment. Blood was drawn before, during and after treatment for measurement of IGF-1 levels and standard hematology and biochemistry parameters. Baseline-adjusted mean body weights and IGF-1 levels were significantly higher in treated as compared with control monkeys after 7 d of beginning treatment (body weight of 10.5±0.1kg (mean ± SEM) and 10.1±0.1kg, respectively; IGF-1 of 758±43ng/mL and 639±22ng/mL, respectively). Capromorelin administration was not associated with appreciable changes in hematologic and biochemical values in treated macaques. These findings suggest that capromorelin may be useful for treating inappetence and weight loss in NHP, and based on blood analysis, a 7-d course of treatment does not appear to cause acute toxicity.</p>\",\"PeriodicalId\":94111,\"journal\":{\"name\":\"Journal of the American Association for Laboratory Animal Science : JAALAS\",\"volume\":\" \",\"pages\":\"268-278\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11193426/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the American Association for Laboratory Animal Science : JAALAS\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.30802/AALAS-JAALAS-23-000010\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/2/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Association for Laboratory Animal Science : JAALAS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30802/AALAS-JAALAS-23-000010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/29 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

由于各种原因,用于生物医学研究的非人灵长类动物可能会出现明显的临床体重减轻。厌食症(完全丧失食欲)或厌食症(食欲减退)的发作会导致体重大幅下降,从而可能改变动物福利和科学研究。美国食品和药物管理局已批准在家养动物中使用几种食欲刺激剂,但目前还没有批准在非家养动物中使用。治疗 NHP 的食欲不振和体重减轻通常依赖于这些化合物的标签外使用。卡普瑞林是一种胃泌素受体激动剂。作为一种生长激素分泌剂,卡波莫瑞林可增加食欲,导致体重增加。在多个物种中进行的研究表明,服用卡波瑞林与体重增加之间存在正相关关系;2017 年,一种卡波瑞林口服溶液获得了美国食品及药物管理局(FDA)的批准,可用于犬类。我们在健康成年猕猴(n = 3 雄 3 雌)中测试了这种溶液对体重和胰岛素样生长因子-1(IGF-1)的影响。对照组(n = 2 雄 2 雌)用于比较。每天观察猕猴的临床症状。在治疗前、治疗期间和治疗结束时收集体重。在治疗前、治疗中和治疗后抽血测量 IGF-1 水平以及标准血液学和生物化学参数。开始治疗 7 天后,经基线调整的治疗猴平均体重和 IGF-1 水平明显高于对照猴(体重分别为 10.5 ± 0.1 kg(平均值 ± SEM)和 10.1 ± 0.1 kg;IGF-1 分别为 758 ± 43 ng/mL 和 639 ± 22 ng/mL)。服用卡泊瑞林后,猕猴的血液学和生化值没有明显变化。这些研究结果表明,卡泊瑞林可用于治疗NHP的食欲不振和体重减轻,而且根据血液分析,7天的疗程似乎不会引起急性毒性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Evaluating the Safety and Efficacy of Capromorelin in Rhesus Macaques (Macaca mulatta).

Nonhuman primates used in biomedical research may experience clinically significant weight loss for a variety of reasons. Episodes of anorexia (complete loss of appetite) or hyporexia (decreased appetite) can result in significant weight loss, potentially altering animal welfare and scientific studies. The FDA has approved several appetite stimulants for use in domestic species, but currently none are approved for use in NHP. Treatment of inappetence and weight loss in NHP often relies on the extralabel use of these compounds. Capromorelin is a ghrelin receptor agonist. As a growth hormone secretagogue, capromorelin increases appetite, leading to weight gain. Studies in several species have shown a positive correlation between capromorelin administration and weight gain; in 2017, an oral solution of capromorelin received FDA approval for use in dogs. We tested this solution in healthy adult rhesus macaques (n = 3 males and 3 females) for its effects on body weight and insulin like growth factor-1 (IGF-1). A control group (n = 2 males and 2 females) was used for comparison. Treated macaques received a 3mg/kg oral dose daily for 7 d. Clinical signs were observed daily. Weights were collected before, during and at the end of treatment. Blood was drawn before, during and after treatment for measurement of IGF-1 levels and standard hematology and biochemistry parameters. Baseline-adjusted mean body weights and IGF-1 levels were significantly higher in treated as compared with control monkeys after 7 d of beginning treatment (body weight of 10.5±0.1kg (mean ± SEM) and 10.1±0.1kg, respectively; IGF-1 of 758±43ng/mL and 639±22ng/mL, respectively). Capromorelin administration was not associated with appreciable changes in hematologic and biochemical values in treated macaques. These findings suggest that capromorelin may be useful for treating inappetence and weight loss in NHP, and based on blood analysis, a 7-d course of treatment does not appear to cause acute toxicity.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信